国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

首頁> 美國衛(wèi)生研究院文獻>Journal of Radiation Research >Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer
【2h】

Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer

機譯：61例下咽癌并發(fā)食管癌的臨床結局

代理獲取
本網(wǎng)站僅為用戶提供外文OA文獻查詢和代理獲取服務，本網(wǎng)站沒有原文。下單后我們將采用程序或人工為您竭誠獲取高質(zhì)量的原文，但由于OA文獻來源多樣且變更頻繁，仍可能出現(xiàn)獲取不到、文獻不完整或與標題不符等情況，如果獲取不到我們將提供退款服務。請知悉。
  • 摘要
  • 著錄項
  • 相似文獻
  • 相關主題

摘要

The aim of this research was to provide data from a single-center study of the treatment of synchronous hypopharyngeal cancer (HPC) and esophageal cancer (EC) with different treatment modalities. A total of 61 patients with synchronous HPC and EC were included in this study. Patients were treated with radiotherapy/chemoradiotherapy (28 cases), surgery (9 cases), palliative radiotherapy and/or chemotherapy (17 cases), or supportive care (7 cases). The median radiotherapy doses for EC and HPC in the radiotherapy/chemoradiotherapy group were 64.5 Gy (range, 0–70) and 70 Gy (range, 60–75.2), respectively. Seven patients in the surgery group received pharyngoesophagectomy with gastric pull-up reconstruction, and two received esophagectomy followed by radiotherapy at the hypopharynx. Cox proportional hazard analysis revealed that the outcome of active treatments, including surgery and radiotherapy/chemoradiotherapy, was better than that of conservative care. In survival analysis, patients in the surgery group tended to have a better 3-year overall survival rate than those in the radiotherapy/chemoradiotherapy group (55.6% vs 30.9%); however, this difference was not statistically different (P = 0.493). The two groups had similar 3-year progression-free survival rates (30.6% and 33.3%, P = 0.420). The current study suggested that radiotherapy/chemoradiotherapy should be considered as an important treatment modality in addition to surgery for synchronous HPC and EC.
機譯：這項研究的目的是提供來自單中心研究的以不同治療方式治療同步下咽癌（HPC）和食道癌（EC）的數(shù)據(jù)。本研究共納入61例同步HPC和EC患者?；颊呓邮芰朔暖?放化療（28例），手術（9例），姑息放療和/或化療（17例）或支持治療（7例）的治療。放療/放化療組中EC和HPC的中位放療劑量分別為64.5 Gy（范圍為0-70）和70 Gy（范圍為60-75.2）。手術組中的7例患者接受了咽上食管切除術并進行了胃上拉重建術，其中2例接受了食管切除術，然后在下咽進行了放療?？伎怂贡壤L險分析顯示，積極治療的結果，包括手術和放療/放化療，比保守治療更好。在生存分析中，手術組患者的3年總生存率往往高于放療/放化療組（55.6％對30.9％）。然而，這種差異在統(tǒng)計學上沒有差異（P = 0.493）。兩組的3年無進展生存率相似（分別為30.6％和33.3％，P = 0.420）。目前的研究表明，放療/放化療是同步HPC和EC手術之外的重要治療手段。

著錄項

相似文獻

  • 外文文獻
  • 中文文獻
  • 專利
代理獲取

客服郵箱：kefu@zhangqiaokeyan.com

京公網(wǎng)安備：11010802029741號 ICP備案號：京ICP備15016152號-6 六維聯(lián)合信息科技 (北京) 有限公司?版權所有

  • 客服微信

  • 服務號